Beyond traditional chelation therapy, recent studies have explored the potential of novel iron regulators, such as hepcidin mimetics and ferroportin inhibitors, to modulate iron homeostasis and reduce oxidative damage in cardiomyopathies [225]. Here, HAMP is linked to cardiomyopathy.